The U.S. Food and Drug Administration (FDA) approved Yartemlea (narsoplimab-wuug) injection to treat adults and children 2 years and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) as the first approved treatment option for TA-TMA.